ANDA 78422, held by Ipca Labs Ltd. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 78422 (Metformin Hydrochloride), held by Ipca Labs Ltd, was first approved by FDA on Aug 6, 2007, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 6, 2007 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet;oral | Metformin Hydrochloride | Discontinued |
| Metformin Hydrochloride850MG · tablet;oral | Metformin Hydrochloride | Discontinued |
| Metformin Hydrochloride1GM · tablet;oral | Metformin Hydrochloride | Discontinued |
| Aug 11, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 25, 2010 | Supplement 1Labeling | Approved | None posted |
| Aug 6, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters